Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Inclusion Criteria: * Males and females, 18-64 years of age. * Females must be: 1. Surgically sterilized 2. Post menopausal: * 12 months of spontaneous amenorrhea or * 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \> 40 milli-International Units (mIU)/ml or * 6 weeks postsurgical bilateral oophorectomy 3\. Those of childbearing potential must have a negative pre-treatment serum pregnancy test followed by a confirmatory urine pregnancy test immediately prior to vaccination and must agree to use a reliable form of contraception for at least 21 days post vaccination including contraceptives, intrauterine device, double-barrier method. * In good health as determined by medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator. * Must sign informed consent indicating understanding of the purpose of and procedures required for the study and willingness to participate. Exclusion Criteria: * Within 6 months preceding the administration of the study vaccine, receiving any licensed or investigational vaccine. * Within 30 days preceding the administration of the study vaccine, receiving any investigational drug. * Excessive chronic alcohol use within the last 5 years. * History of drug abuse, other than recreational cannabis use, within the last 5 years that could affect the subject's participation in the study. * Significant psychiatric illness within the last 12 months which would interfere with the study. * A chronic illness that is not medically stable, receiving a concomitant therapy in which the medication dose has not been stable for at least 3 months prior to immunization or has any other condition that could interfere with the study. * Clinically significant abnormal liver function tests at screening: alanine transaminase (ALT) or aspartate aminotransferase (AST) \>2.5 Upper Limit of Normal (ULN). * Total bilirubin \> 1.5 ULN if ALT or AST \> ULN or total bilirubin \> 2 ULN with ALT and AST within normal range . * Creatinine \>1.7mg/dL, Hemoglobin \< 11g/dL for females; \<12.5 g/dL for males, white blood cells (WBC) \<2500cell/mm3 or \> 15,000cell/mm3, Platelet Count \<125,000cell/mm3 * Positive serology for HBSAg, hepatitis C virus (HCV) or HIV * Have cancer or have received treatment for cancer within three years, excluding in situ cervical carcinoma or basal /squamous cell carcinoma of the skin at other than the vaccination site. * Any autoimmune disease. * Presently receiving or having a recent history of receiving (≤ six months) any medication or therapeutic modality that affects the immune system or a drug known to be frequently associated with significant major organ toxicity or system corticosteroids (oral or injectable). * History of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component. * Allergic to egg or egg products. * History of Guillain-Barré Syndrome. * Receipt of blood or blood products 8 weeks prior to vaccination or planned administration during the three week study period following vaccination * Donation of blood or blood products within 4 weeks prior to vaccination or during the 4 week study period following vaccination. * Acute disease within 72 hours prior to vaccination. * An oral temperature \>100.4°F (38°C) on the day of vaccination * Body Mass Index \>40. * Known bleeding disorders or receiving prescribed oral or parenteral anticoagulants. * Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study or could interfere with study evaluations.